PRISM MarketView – Weekly Market Report
PRISM Market Pulse: Market Tumbles Amid Fed’s Rate Stance; Mixed Corporate Earnings Highlight Sector Struggles New York, N.Y., April 19, 2024 – PRISM MarketView – Equities were down in the morning and into midday as the major indices remain on track to notch their third straight week of declines. Fedspeak continues to support the “higher-for-longer” narrative […]
PRISM MarketView – Bio Investor Alert
New York, N.Y., April 18, 2024 – PRISM MarketView – More than 83,000 new cases of bladder cancer are diagnosed in the US each year, and the illness is responsible for around 17,000 deaths annually. Urothelial carcinoma accounts for 90% of bladder cancers in the US and western Europe, and surgery, followed by chemotherapy or radiation is the current […]
PRISM MarketView – Biotech Breakfast
Mobile-Health Network Solutions (MNDR) IPOs; Q32 Bio Surges; EMA Concludes GLP-1 Drugs Not Associated with Suicidal Thoughts New York, N.Y., April 15, 2024 – PRISM MarketView – Healthcare equities finished lower on Friday, in line with broad declines across the market. The S&P 500 Healthcare Index closed down (1.52%) versus the S&P 500 Index which lost […]
PRISM MARKETVIEW PREVIEWS ANTICIPATED FDA DRUG APPROVALS FOR 2024
New York, N.Y., March 25, 2024 – PRISM MarketView – Drug development is an arduous, costly and time-consuming process for the teams involved behind the scenes, and the patients anxiously awaiting breakthroughs in different disease areas. It takes 12 years on average for a company to take a drug from discovery to commercialization, and every […]
PRISM MarketView Spotlights Companies Leading the Charge in Liver Disease Treatment Following Landmark FDA Approval
New York, N.Y., March 18, 2024 – PRISM MarketView, a leading provider of unbiased market insight and company news, today highlights the FDA’s landmark approval of Rezdiffra™ and the companies leading the charge in developing new, safe, and effective treatments for liver disease. The landmark decision has shone a light on metabolic dysfunction-associated steatohepatitis (MASH), […]
PRISM MarketView Highlights Work of Emerging Companies on Rare Disease Day
New York, N.Y., February 29, 2024 – PRISM MarketView, a leading provider of unbiased market insight and company news, recognizes the remarkable contributions of companies developing treatments for the 10,000 rare diseases affecting more than 30 million Americans. All areas of medicine, and all organs and body systems, are impacted by rare diseases, including rare […]
PRISM MarketView Announces the Addition of Verastem to Emerging Women’s Health Index
New York, N.Y., January 12, 2024 – In concert with Cervical Health Awareness Month, PRISM MarketView has added Verastem, Inc., a biopharmaceutical company focused on the development and commercialization of new medicines for patients combating various types of cancer to its Emerging Women’s Health Index. Some of these cancers include breast, gynecological, colorectal and melanoma. […]
SELLAS Advances Blood Cancer Treatment with “Tremendous Therapeutic Promise”
October 11, 2023 SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) has reported two significant milestones this week as it pursues development of its drug candidate, SLS009 for hematological malignancies. “SLS009 is a novel and highly selective CDK9 inhibitor which, to date, has shown tremendous therapeutic promise across multiple blood cancers.” Angelos Stergiou, MD, ScD h.c., […]
SELLAS SLS009 Phase 1 Clinical Study Successfully Achieves All Primary and Secondary Endpoints
September 22, 2023 Late-stage biopharmaceutical company, SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) has announced positive topline data for the patient group with relapsed/refractory (r/r) lymphomas from its Phase 1 dose-escalation trial of its CDK9 inhibitor, SLS009 (GFH009). We are excited to share strong topline data from the Phase 1 trial of SLS009 in lymphoma patients. The […]